Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BURNING ROCK BIOTECH LIMITED

(BNR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Burning Rock Collaborates with IMPACT Therapeutics to Provide Testing Services in Developing IMP9064 in both US and China

11/04/2021 | 02:07am EST

GUANGZHOU, China, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced a collaboration with IMPACT Therapeutics where Burning Rock provides testing services in connection with IMPACT Therapeutics’ development of its ATR inhibitor IMP9064, which has received the Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) for the Phase I/II clinical study, and will begin soon in the U.S. The collaboration will be supported by Burning Rock’s Clinical Laboratory Improvement Amendments (CLIA) certified and College of American Pathologists (CAP) accredited labs in Guangzhou, China and California, U.S.

IMP9064 is an ATR inhibitor discovered and developed by IMPACT Therapeutics, with worldwide intellectual property rights. In preclinical studies, IMP9064 was found to be a highly potent ATR inhibitor and is selective against other kinases. Additionally, IMP9064 has demonstrated high activities in several ATM-deficient cell lines and more active than reference compound in xenograft in vivo models, which could potentially lead to a wider therapeutic window, better tolerability in long-term administration as a single agent, and providing more flexibility in combination therapy. Senaparib, a PARP inhibitor developed by IMPACT Therapeutics, has been explored in several clinical studies worldwide. IMP9064 in combination with Senaparib will be evaluated in this clinical study to explore the combination therapy of an ATR inhibitor and a PARP inhibitor, which is highly anticipated in the DNA Damage Response (DDR) research field.

The two laboratories of Burning Rock, which are located in Guangzhou, China and California, U.S., have both obtained the certificate issued by the CAP and the CLIA certificate issued by the Centers for Medicare and Medicaid Services (CMS). The certified laboratories have also supported the global strategic partnership with IMPACT Therapeutics in companion diagnostics (CDx) development for a pipeline of drugs in the field of synthetic lethality, including the CDx development of Senaparib. Please refer to the Company’s press release dated August 3, 2021 for further details on the global strategic partnership.

About IMPACT Therapeutics
IMPACT Therapeutics is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. IMPACT Therapeutics has assembled one of the most comprehensive DNA damage response (DDR) global pipeline of novel drug candidates generated by in-house discovery efforts and is expanding to other novel synthetic lethality targets to broaden its pipeline. IMPACT pipeline products include PARP inhibitor (Senaparib/ IMP4297), Wee1 inhibitor (IMP7068), and other novel DDR pathway inhibitors. The lead clinical program, PARP inhibitor (Senaparib/ IMP4297), is in Phase II/III studies for ovarian cancer, prostate cancer, small cell lung cancer and other indications worldwide, including China. Senaparib’s preliminary clinical data demonstrated superior tolerability and wider therapeutic window compared with other PARPi. Phase I study of Wee1 inhibitor (IMP7068) is conducted globally. ATR Inhibitor IMP9064 has received IND Clearance by FDA to start clinical studies in the U.S. and Hedgehog pathway inhibitor (IMP5471) has received IND approval from NMPA to initiate clinical studies in China.

For more information, please visit www.impacttherapeutics.com

About Burning Rock
Burning Rock Biotech Limited (NASDAQ: BNR), whose mission is to guard life via science, focuses on the application of next generation sequencing (NGS) technology in the field of precision oncology. Its business consists of i) NGS-based therapy selection testing for late-stage cancer patients, with the leading market share in China and over 273,000 tissue and liquid-based tests completed cumulatively, and ii) cancer early detection, which has moved beyond proof-of-concept R&D into the clinical validation stage.

For more information about Burning Rock, please visit: ir.brbiotech.com.

Safe Harbor Statement
This press release contains forward-looking statements. These statements constitute “forward-looking” statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “target,” “confident” and similar statements. Burning Rock may also make written or oral forward-looking statements in its periodic reports to the SEC, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about Burning Rock’s beliefs and expectations, are forward-looking statements. Such statements are based upon management’s current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties and other factors, all of which are difficult to predict and many of which are beyond Burning Rock’s control. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. All information provided in this press release is as of the date of this press release, and Burning Rock does not undertake any obligation to update any forward-looking statement as a result of new information, future events or otherwise, except as required under applicable law.

Contact: IR@brbiotech.com


Primary Logo


ę GlobeNewswire 2021
All news about BURNING ROCK BIOTECH LIMITED
2021BURNING ROCK BIOTECH : Announces Results of 2021 Annual General Meeting - Form 6-K
PU
2021Burning Rock Biotech Reaffirms 2021 Revenue Target
MT
2021Burning Rock Reaffirms 2021 Revenue Guidance of RMB500 Million
AQ
2021Burning Rock Biotech Limited Provides Revenue Guidance for 2021
CI
2021Burning Rock Announces Results of 2021 Annual General Meeting
AQ
2021Oncocyte and Burning Rock Complete Technology Transfer Part Two and Prepare for Scaled ..
AQ
2021Merck KGaA, Darmstadt, Germany and Burning Rock Collaborate on Liquid-biopsy Based CDx ..
AQ
2021Health Care Stocks Mixed Pre-Bell Tuesday
MT
2021Burning Rock Biotech Reports Wider Q3 Loss, Higher Revenue
MT
2021BURNING ROCK BIOTECH : Reports Third Quarter 2021 Financial Results - Form 6-K
PU
More news
Analyst Recommendations on BURNING ROCK BIOTECH LIMITED
More recommendations
Financials
Sales 2021 505 M 79,4 M 79,4 M
Net income 2021 -391 M -61,6 M -61,6 M
Net cash 2021 1 220 M 192 M 192 M
P/E ratio 2021 -13,9x
Yield 2021 -
Capitalization 5 486 M 863 M 863 M
EV / Sales 2021 8,45x
EV / Sales 2022 7,33x
Nbr of Employees 938
Free-Float -
Chart BURNING ROCK BIOTECH LIMITED
Duration : Period :
Burning Rock Biotech Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BURNING ROCK BIOTECH LIMITED
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Last Close Price 52,47 CNY
Average target price 157,01 CNY
Spread / Average Target 199%
EPS Revisions
Managers and Directors
Yu Sheng Han Chairman & Chief Executive Officer
Leo Li Chief Financial Officer & Director
Zhi Hong Zhang Chief Technology Officer
Shao Kun Chuai Chief Technology Officer
Wendy Hayes Independent Director
Sector and Competitors